Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: Recent experience at the Istituto Rizzoli

Gaetano Bacci, Stefano Ferrari, Franco Bertoni, Davide Donati, Patrizia Bacchini, Alessandra Longhi, Adalberto Brach del Prever, Cristiana Forni, Simonetta Rimondini

Research output: Contribution to journalArticle

Abstract

Purpose: The results achieved in 44 patients with nonmetastatic peripheral neuroectodermal tumor (PNET) of bone treated with neoadjuvant chemotherapy are reported. Patients and Methods: A six-drug regimen of chemotherapy (vincristine, doxorubicin, dactinomycin, cyclophosphamide, ifosfamide, and etoposide) was administered to all patients. Local treatment consisted of surgery in 20 patients, surgery followed by radiotherapy in 13, and radiotherapy only in 11. Results: At a mean follow-up of 4.5 years (range, 2 to 7 years), 23 patients (52%) remain event-free, 20 have relapsed (45%), and one has died of chemotherapy-related toxicity. The 5-year event- free survival and overall survival were 54.2% and 62.7%, respectively. To assess the prognostic significance of neural differentiation in the family of Ewing's sarcoma, these results have been compared with the outcomes of 138 concomitant patients with typical Ewing's sarcoma (TES) who were treated according to the same protocol. Of these, 103 (75%) remained continuously event-free, 34 (24%) relapsed, and one died of chemotherapy-related toxicity. It follows that PNET patients treated with this chemotherapy regimen have a significantly worse prognosis than typical ES patients (5-year overall survival, 54.2% v 70.6%, P <.012; 5-year overall survival, 62.7% v 78.3%, P <.002). Conclusion: The authors conclude that studies into new adjuvant therapy for Ewing's sarcoma modulated according to risk of relapse should also consider neural differentiation as a risk factor. (C) 2000 American Society of Clinical Oncology.

Original languageEnglish
Pages (from-to)885-892
Number of pages8
JournalJournal of Clinical Oncology
Volume18
Issue number4
Publication statusPublished - Feb 2000

Fingerprint

Peripheral Primitive Neuroectodermal Tumors
Bone and Bones
Drug Therapy
Ewing's Sarcoma
Survival
Radiotherapy
Ifosfamide
Dactinomycin
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone : Recent experience at the Istituto Rizzoli. / Bacci, Gaetano; Ferrari, Stefano; Bertoni, Franco; Donati, Davide; Bacchini, Patrizia; Longhi, Alessandra; del Prever, Adalberto Brach; Forni, Cristiana; Rimondini, Simonetta.

In: Journal of Clinical Oncology, Vol. 18, No. 4, 02.2000, p. 885-892.

Research output: Contribution to journalArticle

Bacci, Gaetano ; Ferrari, Stefano ; Bertoni, Franco ; Donati, Davide ; Bacchini, Patrizia ; Longhi, Alessandra ; del Prever, Adalberto Brach ; Forni, Cristiana ; Rimondini, Simonetta. / Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone : Recent experience at the Istituto Rizzoli. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 4. pp. 885-892.
@article{b2e400c60a654c0d8eda4a1be2d6de2c,
title = "Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: Recent experience at the Istituto Rizzoli",
abstract = "Purpose: The results achieved in 44 patients with nonmetastatic peripheral neuroectodermal tumor (PNET) of bone treated with neoadjuvant chemotherapy are reported. Patients and Methods: A six-drug regimen of chemotherapy (vincristine, doxorubicin, dactinomycin, cyclophosphamide, ifosfamide, and etoposide) was administered to all patients. Local treatment consisted of surgery in 20 patients, surgery followed by radiotherapy in 13, and radiotherapy only in 11. Results: At a mean follow-up of 4.5 years (range, 2 to 7 years), 23 patients (52{\%}) remain event-free, 20 have relapsed (45{\%}), and one has died of chemotherapy-related toxicity. The 5-year event- free survival and overall survival were 54.2{\%} and 62.7{\%}, respectively. To assess the prognostic significance of neural differentiation in the family of Ewing's sarcoma, these results have been compared with the outcomes of 138 concomitant patients with typical Ewing's sarcoma (TES) who were treated according to the same protocol. Of these, 103 (75{\%}) remained continuously event-free, 34 (24{\%}) relapsed, and one died of chemotherapy-related toxicity. It follows that PNET patients treated with this chemotherapy regimen have a significantly worse prognosis than typical ES patients (5-year overall survival, 54.2{\%} v 70.6{\%}, P <.012; 5-year overall survival, 62.7{\%} v 78.3{\%}, P <.002). Conclusion: The authors conclude that studies into new adjuvant therapy for Ewing's sarcoma modulated according to risk of relapse should also consider neural differentiation as a risk factor. (C) 2000 American Society of Clinical Oncology.",
author = "Gaetano Bacci and Stefano Ferrari and Franco Bertoni and Davide Donati and Patrizia Bacchini and Alessandra Longhi and {del Prever}, {Adalberto Brach} and Cristiana Forni and Simonetta Rimondini",
year = "2000",
month = "2",
language = "English",
volume = "18",
pages = "885--892",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone

T2 - Recent experience at the Istituto Rizzoli

AU - Bacci, Gaetano

AU - Ferrari, Stefano

AU - Bertoni, Franco

AU - Donati, Davide

AU - Bacchini, Patrizia

AU - Longhi, Alessandra

AU - del Prever, Adalberto Brach

AU - Forni, Cristiana

AU - Rimondini, Simonetta

PY - 2000/2

Y1 - 2000/2

N2 - Purpose: The results achieved in 44 patients with nonmetastatic peripheral neuroectodermal tumor (PNET) of bone treated with neoadjuvant chemotherapy are reported. Patients and Methods: A six-drug regimen of chemotherapy (vincristine, doxorubicin, dactinomycin, cyclophosphamide, ifosfamide, and etoposide) was administered to all patients. Local treatment consisted of surgery in 20 patients, surgery followed by radiotherapy in 13, and radiotherapy only in 11. Results: At a mean follow-up of 4.5 years (range, 2 to 7 years), 23 patients (52%) remain event-free, 20 have relapsed (45%), and one has died of chemotherapy-related toxicity. The 5-year event- free survival and overall survival were 54.2% and 62.7%, respectively. To assess the prognostic significance of neural differentiation in the family of Ewing's sarcoma, these results have been compared with the outcomes of 138 concomitant patients with typical Ewing's sarcoma (TES) who were treated according to the same protocol. Of these, 103 (75%) remained continuously event-free, 34 (24%) relapsed, and one died of chemotherapy-related toxicity. It follows that PNET patients treated with this chemotherapy regimen have a significantly worse prognosis than typical ES patients (5-year overall survival, 54.2% v 70.6%, P <.012; 5-year overall survival, 62.7% v 78.3%, P <.002). Conclusion: The authors conclude that studies into new adjuvant therapy for Ewing's sarcoma modulated according to risk of relapse should also consider neural differentiation as a risk factor. (C) 2000 American Society of Clinical Oncology.

AB - Purpose: The results achieved in 44 patients with nonmetastatic peripheral neuroectodermal tumor (PNET) of bone treated with neoadjuvant chemotherapy are reported. Patients and Methods: A six-drug regimen of chemotherapy (vincristine, doxorubicin, dactinomycin, cyclophosphamide, ifosfamide, and etoposide) was administered to all patients. Local treatment consisted of surgery in 20 patients, surgery followed by radiotherapy in 13, and radiotherapy only in 11. Results: At a mean follow-up of 4.5 years (range, 2 to 7 years), 23 patients (52%) remain event-free, 20 have relapsed (45%), and one has died of chemotherapy-related toxicity. The 5-year event- free survival and overall survival were 54.2% and 62.7%, respectively. To assess the prognostic significance of neural differentiation in the family of Ewing's sarcoma, these results have been compared with the outcomes of 138 concomitant patients with typical Ewing's sarcoma (TES) who were treated according to the same protocol. Of these, 103 (75%) remained continuously event-free, 34 (24%) relapsed, and one died of chemotherapy-related toxicity. It follows that PNET patients treated with this chemotherapy regimen have a significantly worse prognosis than typical ES patients (5-year overall survival, 54.2% v 70.6%, P <.012; 5-year overall survival, 62.7% v 78.3%, P <.002). Conclusion: The authors conclude that studies into new adjuvant therapy for Ewing's sarcoma modulated according to risk of relapse should also consider neural differentiation as a risk factor. (C) 2000 American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0033953197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033953197&partnerID=8YFLogxK

M3 - Article

C2 - 10673532

AN - SCOPUS:0033953197

VL - 18

SP - 885

EP - 892

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -